Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 USD | -10.67% |
|
+1.92% | +169.49% |
05-21 | DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis | CI |
05-21 | Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+169.49% | 49.35M | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- DRRX Stock
- News DURECT Corporation
- Durect Gets FDA Breakthrough Therapy Designation for Alcohol-Related Hepatitis Treatment